Brought to you by 
SpePharm gets rights to TopoTarget's Savene
30 Jan 2023
Executive Summary
Specialty pharmaco SpePharm Holding BV has licensed worldwide rights (excluding North and South America) to exclusively develop and commercialize TopoTarget's cancer therapy Savene (dexrazoxane). It also takes on TopoTarget's European sales team.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SpePharm gets rights to TopoTarget's Savene
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice